NCT03722576View on ClinicalTrials.gov

Vidofludimus Calcium for Primary Sclerosing Cholangitis

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 17, 2019

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Primary Sclerosing Cholangitis
Interventions
DRUG

Vidofludimus calcium

During the 6-month treatment period, subjects will receive 30 mg VC orally once daily. This will be preceded by a lead-in dosing period where subjects will receive 15 mg VC once daily for 1 week.

Trial Locations (3)

55905

Mayo Clinic in Rochester, Rochester

85259

Mayo Clinic in Arizona, Phoenix

85281

Arizona State University, Tempe

All Listed Sponsors
collaborator

Arizona State University

OTHER

lead

Elizabeth Carey

OTHER

NCT03722576 - Vidofludimus Calcium for Primary Sclerosing Cholangitis | Biotech Hunter | Biotech Hunter